ExpreS2ion Biotechnologies and Oxford's Jenner Institute Enter Licensing Agreement

Biotech company ExpreS2ion Biotechnologies today announced that they have signed a research license agreement to provide the University of Oxford access to ExpreS2ion's Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production.

The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford. The platform will be used by various research teams to address expression of complex and "difficult-to-make" proteins.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.